3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
23
Phase 3
5
Phase 1/2
5
Phase 2/3
3
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
59
Pancreatic Neoplasms
33
Colonic Neoplasms
31
Rectal Neoplasms
30
Stomach Neoplasms
22
Neoplasm Metastasis
19
Carcinoma, Non-Small-Cell Lung
19
Neoplasms
16
Unspecified Adult Solid Tumor, Protocol Specific
15
Esophageal Neoplasms
12
Ovarian Neoplasms
8
Gallbladder Neoplasms
7
Appendiceal Neoplasms
7
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Breast Neoplasms
6
Bile Duct Neoplasms
6
Peritoneal Neoplasms
5
Liver Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Hepatocellular
5
Adenocarcinoma
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Fallopian Tube Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Pancreatic Ductal
4
Squamous Cell Carcinoma of Head and Neck
3
Interventions
Gemcitabine
13
Cisplatin
9
Capecitabine
7
durvalumab
6
pembrolizumab
4
tremelimumab
3
S 1 (combination)
3
Nivolumab
3
AZD 6244
3
Ramucirumab
2
Fluorouracil
2
130-nm albumin-bound paclitaxel
2
vandetanib
1
trifluridine tipiracil drug combination
1
trametinib
1
tocilizumab
1
titanium silicide
1
sacituzumab govitecan
1
poly ICLC
1
futibatinib
1
fludarabine
1
cemiplimab
1
binimetinib
1
aflibercept
1
Tegafur
1
TAS-116
1
Psilocybin
1
Peptides
1
Oxaliplatin
1
NUC-1031
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Biliary Tract Neoplasms
×
Oxaliplatin
×
Clear all
NCT03162510
2022-04-07
SOLAR
National Health Research Institutes, Taiwan
Phase 1
Completed
18 enrolled